Springboard Capital

AxoGen, Inc. is a company focused on developing and commercializing innovative solutions for the repair and regeneration of peripheral nerve injuries. Based in Alachua, Florida, and founded in 2002, AxoGen offers a range of products designed for effective surgical procedures, including the AVANCE Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. Additionally, it provides the Axotouch Two-Point Discriminator, a device used to assess the innervation density of skin. AxoGen's offerings are aimed at surgeons and healthcare providers, ensuring clinically and economically effective solutions for nerve repair. The company also has a strategic partnership with the American Tissue Services Foundation for tissue recovery and distributes its products across the United States and several international markets, including Canada, Germany, the United Kingdom, Spain, and South Korea.

Consolidated Asset Recovery Systems is a software company based in Raleigh, North Carolina, specializing in solutions for the repossession and remarketing industry. Founded in 2005 by Steve Norwood and Terry Groves, the company develops Internet Based Electronic Asset Management (IBEAM) technology to track and recover assets for banks and dealers. Its services include repossession management, electronic invoicing, skip tracing, audits, legal demands, automated notices, and field assistance. The company supports a network of recovery agents across the United States and serves lenders, dealers, and repossession/recovery agents. Consolidated Asset Recovery Systems operates offices in California, Texas, Colorado, and Florida, with a team of 50 employees. It is known for its growth and profitability, adhering to compliant service providers and offering both software and services tailored to lenders' needs. The company has been recognized with numerous industry awards.

Amulet Pharmaceuticals discovers and develops novel therapeutics using their NORTECHâ„¢ technology to address known liabilities of current therapies serving large unmet markets. Their lead program (AMU-301) treats diabetic gastroparesis an unmet complication of diabetes affecting over 3 million women in the United States.